MOONLAKE IMMUNOTHERAPEUTICS's ticker is and the CUSIP is 61559X104. A total of 122 filers reported holding MOONLAKE IMMUNOTHERAPEUTICS in Q3 2023. The put-call ratio across all filers is 13.14 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,385,164 | – | 164,652 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BVF INC/IL | 21,751,284 | $1,239,823,188 | 33.43% |
| Cormorant Asset Management, LP | 8,142,100 | $464,099,700 | 27.07% |
| Ally Bridge Group (NY) LLC | 183,105 | $10,436,985 | 12.25% |
| Finepoint Capital LP | 331,416 | $18,890,712 | 9.41% |
| Ghost Tree Capital, LLC | 330,000 | $18,810,000 | 6.19% |
| 5AM Venture Management, LLC | 313,210 | $17,852,970 | 5.14% |
| Ghost Tree Capital, LLC | 250,000 | $14,250,000 | 4.69% |
| MPM BioImpact LLC | 294,190 | $16,768,830 | 4.48% |
| Integral Health Asset Management, LLC | 500,000 | $28,500,000 | 3.95% |
| Altium Capital Management LP | 88,000 | $5,016,000 | 2.62% |